CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- 4 Open-market sale EVP, General Counsel sold 2,078 shares at $55.86 ($116,077)
- 4 Option exercise EVP, Chief Operating Officer acquired 1,500 shares (option exercise)
- 4 Open-market sale Director sold 88,764 shares at an average $53.55 ($4,753,680)
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 4 Open-market sale EVP, General Counsel sold 3,364 shares at an average $38.21 ($128,525)
- 8-K Event Material agreement · Other events
- 424B5 Offering Prospectus
- 424B5 Offering Prospectus
- S-3ASR Offering Registration Statement
- 4 Open-market sale President and CEO sold 35,000 shares at an average $38.57 ($1,350,000)
- 4 Open-market sale President and CEO sold 50,000 shares at $36.00 ($1,800,000)
- 4 Open-market sale President and CEO sold 20,000 shares at $34.00 ($680,000)
- 4 Open-market sale EVP, General Counsel sold 6,653 shares at an average $34.36 ($228,568)
- 8-K Event Other events
- 4 Open-market sale EVP, General Counsel sold 3,364 shares at $28.00 ($94,192)
- 4 Open-market sale President and CEO sold 50,000 shares at $26.00 ($1,300,000)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 8-K Event Other events
Page 21 of 37 · 725 filings